$Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)$
Código QR

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)

Moataz E Gheith, Jason R Mayer, Ghada A Siam, Daniela S Monteiro de Barros,&nbsp; Tricia L Thomas, L Jay KatzFrom the Glaucoma Service Department of Wills Eye Institute, Jefferson Medical College, Philadelphia, PA, USAAbstract: Glaucoma is a chronic progressive optic neuropathy characterized...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Moataz E Gheith, Jason R Mayer, Ghada A Siam, Daniela S Monteiro de Barros, Tricia L Thomas, L Jay Katz
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/9b1703a1ec80495eac0001d11f943bb1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9b1703a1ec80495eac0001d11f943bb1
record_format	dspace
spelling	oai:doaj.org-article:9b1703a1ec80495eac0001d11f943bb12021-12-02T07:48:03ZManaging refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)1177-54671177-5483https://doaj.org/article/9b1703a1ec80495eac0001d11f943bb12008-03-01T00:00:00Zhttp://www.dovepress.com/managing-refractory-glaucoma-with-a-fixed-combination-of-bimatoprost-0-a362https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Moataz E Gheith, Jason R Mayer, Ghada A Siam, Daniela S Monteiro de Barros,&nbsp; Tricia L Thomas, L Jay KatzFrom the Glaucoma Service Department of Wills Eye Institute, Jefferson Medical College, Philadelphia, PA, USAAbstract: Glaucoma is a chronic progressive optic neuropathy characterized by progressive loss of retinal ganglion cells, which manifests clinically with loss of optic disc neuroretinal rim tissue, defects in the retinal nerve fiber layer, and deficits on functional visual field testing. The goal of glaucoma treatment is to reduce the intraocular pressure to a level that prevents or minimizes the progressive loss of vision. The current standard of management for the newly diagnosed primary open angle glaucoma (PAOG) patient is to start topical medication. Available topical medications include: beta-adrenergic antagonists, alpha-adrenergic agonists, carbonic anhydraze inhibitors, prostaglandin analogues and miotics. In some patients, IOP is not adequately controlled by monotherapy. In those refractory patients, where more efficacy is required, shifting to another medication or adding a second medication is indicated. The complimentary action between two drugs serves as the basis for combination medications. One avenue of delivering a second medication is through a fixed combination medication that has the advantage of providing two medicines within one drop. Bimatoprost/timolol represents a new fixed combination which is clinically and statistically more effective than either of its active constituents for patients with refractory glaucoma. As regard the safety of the combination, there were no signs or symptoms of intolerance and the incidence of conjunctival hyperemia was clinically and statistically significantly less than each of the two components separately. Bimatoprost/timolol fixed combination offers cost and time savings, which may enhance compliance; also reducing the amount of preservative applied to the eye, will improve tolerability and may also favorably improve eventual surgical outcomes in patients who might require filtering procedures.Keywords: fixed combination, refractory glaucoma, timolol/bimatoprost Moataz E GheithJason R MayerGhada A SiamDaniela S Monteiro de BarrosTricia L ThomasL Jay KatzDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2008, Iss Issue 1, Pp 15-19 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Moataz E Gheith Jason R Mayer Ghada A Siam Daniela S Monteiro de Barros Tricia L Thomas L Jay Katz Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
description	Moataz E Gheith, Jason R Mayer, Ghada A Siam, Daniela S Monteiro de Barros,&nbsp; Tricia L Thomas, L Jay KatzFrom the Glaucoma Service Department of Wills Eye Institute, Jefferson Medical College, Philadelphia, PA, USAAbstract: Glaucoma is a chronic progressive optic neuropathy characterized by progressive loss of retinal ganglion cells, which manifests clinically with loss of optic disc neuroretinal rim tissue, defects in the retinal nerve fiber layer, and deficits on functional visual field testing. The goal of glaucoma treatment is to reduce the intraocular pressure to a level that prevents or minimizes the progressive loss of vision. The current standard of management for the newly diagnosed primary open angle glaucoma (PAOG) patient is to start topical medication. Available topical medications include: beta-adrenergic antagonists, alpha-adrenergic agonists, carbonic anhydraze inhibitors, prostaglandin analogues and miotics. In some patients, IOP is not adequately controlled by monotherapy. In those refractory patients, where more efficacy is required, shifting to another medication or adding a second medication is indicated. The complimentary action between two drugs serves as the basis for combination medications. One avenue of delivering a second medication is through a fixed combination medication that has the advantage of providing two medicines within one drop. Bimatoprost/timolol represents a new fixed combination which is clinically and statistically more effective than either of its active constituents for patients with refractory glaucoma. As regard the safety of the combination, there were no signs or symptoms of intolerance and the incidence of conjunctival hyperemia was clinically and statistically significantly less than each of the two components separately. Bimatoprost/timolol fixed combination offers cost and time savings, which may enhance compliance; also reducing the amount of preservative applied to the eye, will improve tolerability and may also favorably improve eventual surgical outcomes in patients who might require filtering procedures.Keywords: fixed combination, refractory glaucoma, timolol/bimatoprost
format	article
author	Moataz E Gheith Jason R Mayer Ghada A Siam Daniela S Monteiro de Barros Tricia L Thomas L Jay Katz
author_facet	Moataz E Gheith Jason R Mayer Ghada A Siam Daniela S Monteiro de Barros Tricia L Thomas L Jay Katz
author_sort	Moataz E Gheith
title	Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
title_short	Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
title_full	Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
title_fullStr	Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
title_full_unstemmed	Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
title_sort	managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/9b1703a1ec80495eac0001d11f943bb1
work_keys_str_mv	AT moatazegheith managingrefractoryglaucomawithafixedcombinationofbimatoprost003andtimolol05 AT jasonrmayer managingrefractoryglaucomawithafixedcombinationofbimatoprost003andtimolol05 AT ghadaasiam managingrefractoryglaucomawithafixedcombinationofbimatoprost003andtimolol05 AT danielasmonteirodebarros managingrefractoryglaucomawithafixedcombinationofbimatoprost003andtimolol05 AT tricialthomas managingrefractoryglaucomawithafixedcombinationofbimatoprost003andtimolol05 AT ljaykatz managingrefractoryglaucomawithafixedcombinationofbimatoprost003andtimolol05
_version_	1718399176129118208

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)

Ejemplares similares